Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 15;16(5):1531-1549.
doi: 10.62347/DICU9510. eCollection 2024.

Liquid biopsy to personalize treatment for metastatic prostate cancer

Marta Lopez-Valcarcel  1 , Fernando Lopez-Campos  2 , Juan Zafra  3 , Irene Cienfuegos  4 , Maria Ferri  5 , Marta Barrado  6 , Susana Hernando  7 , Felipe Counago  8
Affiliations
Review

Liquid biopsy to personalize treatment for metastatic prostate cancer

Marta Lopez-Valcarcel et al. Am J Transl Res. .

Abstract

Liquid biopsy is an innovative approach that provides a more complete understanding of treatment response and prognosis in monitoring metastatic prostate cancer. It complements invasive tissue biopsy and involves the assessment of various biomarkers in body fluids such as blood, semen, and urine. Liquid biopsy analyzes circulating tumor cells, extracellular vesicles, circulating tumor DNA, and the secretome. This is particularly important given the heterogeneity of prostate cancer and the need for better prognostic biomarkers. Liquid biopsy can personalize the treatment of homonosensitive and castration-resistant metastatic prostate cancer by acting as a predictive and prognostic tool. This review discusses various biomarkers, assay techniques, and potential applications in daily clinical practice, highlighting the exciting possibilities that this emerging field holds for improving patient outcomes.

Keywords: Liquid biopsy; circulating tumor DNA; circulating tumor cells; extracellular vesicles; prostate cancer; secretome.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Fluids for liquid biopsy in metastatic prostate cancer: semen, blood, and urine. Biomarkers in liquid biopsy: CTC, ctDNA/cfDNA, EV, and secretome.
See this image and copyright information in PMC

References

    1. He W, Xiao Y, Yan S, Zhu Y, Ren S. Cell-free DNA in the management of prostate cancer: current status and future prospective. Asian J Urol. 2023;10:298–316. - PMC - PubMed
    1. Rzhevskiy AS, Kapitannikova AY, Butnaru DV, Shpot EV, Joosse SA, Zvyagin AV, Ebrahimi Warkiani M. Liquid biopsy in diagnosis and prognosis of non-metastatic prostate cancer. Biomedicines. 2022;10:3115. - PMC - PubMed
    1. Dathathri E, Isebia KT, Abali F, Lolkema MP, Martens JWM, Terstappen LWMM, Bansal R. Liquid biopsy based circulating biomarkers in metastatic prostate cancer. Front Oncol. 2022;12:863472. - PMC - PubMed
    1. Puche-Sanz I, Rodríguez-Martínez A, Garrido-Navas MC, Robles-Fernández I, Vázquez-Alonso F, Álvarez Cubero MJ, Lorente-Acosta JA, Serrano-Fernández MJ, Cózar-Olmo JM. Liquid biopsy and prostate cancer. Current evidence applied to clinical practice. Actas Urol Esp (Engl Ed) 2020;44:139–47. - PubMed
    1. Wang Y, Wang Z, Gang X, Wang G. Liquid biopsy in prostate cancer: current status and future challenges of clinical application. Aging Male. 2021;24:58–71. - PubMed

LinkOut - more resources